HC Wainwright Expects Lower Earnings for NRx Pharmaceuticals

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – HC Wainwright cut their Q2 2027 earnings estimates for shares of NRx Pharmaceuticals in a research report issued on Tuesday, November 3rd. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.17) for the quarter, down from their previous forecast of ($0.15). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.04) EPS, FY2027 earnings at ($0.62) EPS and FY2028 earnings at $0.03 EPS.

Other equities analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Tuesday. Wolfe Research started coverage on NRx Pharmaceuticals in a research report on Thursday, October 15th. They set an “outperform” rating for the company. Zacks Research cut NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 26th. Wall Street Zen downgraded NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, UBS Group reissued a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 26th. Six investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $34.50.

NRx Pharmaceuticals Stock Performance

Shares of NRXP opened at $2.49 on Thursday. The stock has a market cap of $107.82 million, a PE ratio of -4.53 and a beta of 2.11. NRx Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $5.05. The firm’s 50-day simple moving average is $2.98 and its two-hundred day simple moving average is $2.96.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.33 million.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Commonwealth Equity Services LLC raised its holdings in NRx Pharmaceuticals by 30.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 590,768 shares of the company’s stock worth $1,725,000 after acquiring an additional 136,350 shares during the last quarter. Prime Capital Investment Advisors LLC purchased a new stake in NRx Pharmaceuticals during the 3rd quarter valued at $364,000. SBI Securities Co. Ltd. boosted its stake in NRx Pharmaceuticals by 292.1% during the 3rd quarter. SBI Securities Co. Ltd. now owns 20,001 shares of the company’s stock valued at $58,000 after purchasing an additional 14,900 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in NRx Pharmaceuticals during the 2nd quarter valued at $54,000. Finally, Ethos Financial Group LLC increased its holdings in shares of NRx Pharmaceuticals by 33.6% in the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after purchasing an additional 4,000 shares in the last quarter. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly severe depression and suicidal ideation. The company’s research programs are designed to address conditions in which existing therapies may have limited effectiveness or delayed onset.

NRx’s lead investigational product is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for bipolar depression with acute suicidal ideation.